MEZNUVIG
Live / Allowed — Second extension granted (statement of use) (as of 27 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Apr 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98519044
- Mark type
- Word mark
- Filed
- 25 Apr 2024
- Published for opposition
- 08 Apr 2025
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis.
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Prosecution history
- 27 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 May 2026 — SOU EXTENSION 2 GRANTED
- 27 May 2026 — SOU EXTENSION 2 FILED
- 27 May 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Nov 2025 — SOU EXTENSION 1 GRANTED
- 12 Nov 2025 — SOU EXTENSION 1 FILED
- 12 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Apr 2025 — PUBLISHED FOR OPPOSITION
- 02 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE